{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:57:12Z","timestamp":1786132632349,"version":"build-2736575974"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","funder":[{"name":"Keryx Biopharmaceuticals, Inc.","award":["investigator-initiated grant"],"award-info":[{"award-number":["investigator-initiated grant"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JASN"],"published-print":{"date-parts":[[2019,8]]},"abstract":"\n Significance Statement<\/jats:title>\n \n Evidence suggests that anemia and disordered mineral metabolism (including abnormalities in phosphate and fibroblast growth factor 23 [FGF23]) contribute to adverse outcomes in patients with advanced CKD. To investigate the effects of fixed-dose ferric citrate coordination complex in such patients, the authors randomly assigned 199 patients with eGFR<20 ml\/min per 1.73 m\n 2<\/jats:sup>\n 2:1 to ferric citrate coordination complex or usual care. Treatment with ferric citrate coordination complex significantly increased hemoglobin, ferritin, and transferrin saturation and significantly reduced FGF23, while maintaining serum phosphate in the normal range in the majority of patients. It also significantly reduced use of erythropoiesis-stimulating agents and intravenous iron, hospital admissions, hospital days, and time to the composite end point of death, provision of dialysis, or kidney transplantation. These findings support the conduct of a placebo-controlled trial using ferric citrate coordination complex in advanced CKD.\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n Researchers have yet to determine the optimal care of patients with advanced CKD. Evidence suggests that anemia and CKD\u2013related disordered mineral metabolism (including abnormalities in phosphate and fibroblast growth factor 23 [FGF23]) contribute to adverse outcomes in this population.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n To investigate whether fixed-dose ferric citrate coordination complex favorably affects multiple biochemical parameters in patients with advanced CKD, we randomly assigned 203 patients with eGFR\u226420 ml\/min per 1.73 m\n 2<\/jats:sup>\n 2:1 to receive a fixed dose of ferric citrate coordination complex (two tablets per meal, 210 mg ferric iron per tablet) or usual care for 9 months or until 3 months after starting dialysis. No single biochemical end point was designated as primary; sample size was determined empirically.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The two groups had generally similar baseline characteristics, although diabetes and peripheral vascular disease were more common in the usual-care group. Ferric citrate coordination complex significantly increased hemoglobin, transferrin saturation, and serum ferritin, and it significantly reduced serum phosphate and intact FGF23 (\n P<\/jats:italic>\n <0.001 for all). Of the 133 patients randomized to ferric citrate coordination complex, 31 (23%) initiated dialysis during the study period, as did 32 of 66 (48%) patients randomized to usual care (\n P<\/jats:italic>\n =0.001). Compared with usual care, ferric citrate coordination complex treatment resulted in significantly fewer annualized hospital admissions, fewer days in hospital, and a lower incidence of the composite end point of death, provision of dialysis, or transplantation (\n P<\/jats:italic>\n =0.002).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The beneficial effects of fixed-dose ferric citrate coordination complex on biochemical parameters, as well as the exploratory results regarding the composite end point and hospitalization, suggest that fixed-dose ferric citrate coordination complex has an excellent safety profile in an unselected population with advanced CKD and merits further study.<\/jats:p>\n <\/jats:sec>","DOI":"10.1681\/asn.2018101016","type":"journal-article","created":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T14:54:03Z","timestamp":1562856843000},"page":"1495-1504","source":"Crossref","is-referenced-by-count":70,"title":["A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD"],"prefix":"10.1681","volume":"30","author":[{"given":"Geoffrey A.","family":"Block","sequence":"first","affiliation":[{"name":"Reata Pharmaceuticals, Dallas, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha S.","family":"Block","sequence":"additional","affiliation":[{"name":"Denver Nephrology Research Division, Denver, Colorado;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Smits","sequence":"additional","affiliation":[{"name":"CSC, Inc., Santa Barbara, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupal","family":"Mehta","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine and Center for Translational Metabolism and Health, Institute of Public Health and Medicine, Feinberg School of Medicine, Jesse Brown Veterans Administration Medical Center,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Isakova","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine and Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myles","family":"Wolf","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, and Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn M.","family":"Chertow","sequence":"additional","affiliation":[{"name":"Stanford University, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,7,5]]},"reference":[{"key":"B1-20231016","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"B2-20231016","first-page":"279","article-title":"KDIGO clinical practice guideline for anemia in chronic kidney disease.","volume":"76","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"4","key":"B3-20231016","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).","volume":"2","year":"2009","journal-title":"Kidney Int Suppl"},{"key":"B4-20231016","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.","volume":"339","author":"Besarab","year":"1998","journal-title":"N Engl J Med"},{"key":"B5-20231016","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia.","volume":"355","author":"Dr\u00fceke","year":"2006","journal-title":"N Engl J Med"},{"key":"B6-20231016","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"B7-20231016","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1159\/000351175","article-title":"Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease.","volume":"37","author":"McCullough","year":"2013","journal-title":"Am J Nephrol"},{"key":"B8-20231016","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1681\/ASN.2013050465","article-title":"Fibroblast growth factor 23 and cardiovascular events in CKD.","volume":"25","author":"Scialla","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B9-20231016","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2215\/CJN.07810910","article-title":"Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction.","volume":"6","author":"Bellasi","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"B10-20231016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jama.2015.18202","article-title":"Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure: A Meta-Analysis.","volume":"315","author":"Tangri","year":"2016","journal-title":"JAMA"},{"key":"B11-20231016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188712","article-title":"Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease.","volume":"12","author":"Chertow","year":"2017","journal-title":"PLoS One"},{"key":"B12-20231016","doi-asserted-by":"crossref","first-page":"i16","DOI":"10.1093\/ndt\/gfw123.05","article-title":"Anemia prevalence and treatment among patients with chronic kidney disease stage 3-5: Data from the Chronic Kidney Disease Outcomes and Practice Patterns Study (CKDOPPS).","volume":"31","author":"Wong","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"B13-20231016","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","article-title":"FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.","volume":"29","author":"Macdougall","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"B14-20231016","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/ndt\/gfw264","article-title":"Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: An analysis of the 1-year FIND-CKD trial.","volume":"32","author":"Roger","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"B16-20231016","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000489223","article-title":"Association of pre-end-stage renal disease hemoglobin with early dialysis outcomes.","volume":"47","author":"Kleine","year":"2018","journal-title":"Am J Nephrol"},{"key":"B17-20231016","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1681\/ASN.2013060569","article-title":"Hepatectomy-related hypophosphatemia: A novel phosphaturic factor in the liver-kidney axis.","volume":"25","author":"Nomura","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B18-20231016","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.kint.2017.11.022","article-title":"The sodium phosphate cotransporter family and nicotinamide phosphoribosyltransferase contribute to the daily oscillation of plasma inorganic phosphate concentration.","volume":"93","author":"Miyagawa","year":"2018","journal-title":"Kidney Int"},{"key":"B19-20231016","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1681\/ASN.2011020175","article-title":"Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition.","volume":"22","author":"Zoccali","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"B20-20231016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074996","article-title":"Serum phosphate as a risk factor for cardiovascular events in people with and without chronic kidney disease: A large community based cohort study.","volume":"8","author":"McGovern","year":"2013","journal-title":"PLoS One"},{"key":"B21-20231016","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.2215\/CJN.00810110","article-title":"Serum phosphate and mortality in patients with chronic kidney disease.","volume":"5","author":"Eddington","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B22-20231016","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1093\/ndt\/gfq808","article-title":"Serum phosphorus predicts incident chronic kidney disease and end-stage renal disease.","volume":"26","author":"O\u2019Seaghdha","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"B23-20231016","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1053\/j.ajkd.2015.01.009","article-title":"Serum phosphorus and progression of CKD and mortality: A meta-analysis of cohort studies.","volume":"66","author":"Da","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"B24-20231016","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.atherosclerosis.2018.02.009","article-title":"Risk factors for progression of coronary artery calcification in patients with chronic kidney disease: The CRIC study.","volume":"271","author":"Bundy","year":"2018","journal-title":"Atherosclerosis"},{"key":"B25-20231016","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1681\/ASN.2017121254","article-title":"A controlled increase in dietary phosphate elevates BP in healthy human subjects.","volume":"29","author":"Mohammad","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B26-20231016","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1053\/j.ajkd.2013.03.042","article-title":"Phosphate homeostasis in CKD: Report of a scientific symposium sponsored by the National Kidney Foundation.","volume":"62","author":"Block","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"B27-20231016","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2014.10.014","article-title":"A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.","volume":"65","author":"Block","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"B28-20231016","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1542-4758.2009.00387.x","article-title":"A randomized double-blind pilot study of serum phosphorus normalization in chronic kidney disease: A new paradigm for clinical outcomes studies in nephrology.","volume":"13","author":"Block","year":"2009","journal-title":"Hemodial Int"},{"key":"B29-20231016","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1681\/ASN.2012030223","article-title":"Effects of phosphate binders in moderate CKD.","volume":"23","author":"Block","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B30-20231016","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy.","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest"},{"key":"B31-20231016","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1681\/ASN.2006080936","article-title":"Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) study.","volume":"18","author":"Fliser","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"B33-20231016","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1681\/ASN.2017070772","article-title":"Longitudinal FGF23 trajectories and mortality in patients with CKD.","volume":"79","author":"Isakova","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B34-20231016","article-title":"Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: Path analyses [published online ahead of print October 30, 2018].","author":"Block","journal-title":"Nephrol Dial Transplant"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201908000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:22:03Z","timestamp":1786130523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201908000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,5]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2018101016","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,5]]}}}